HK1003032A1 - Novel antigens and methods for their preparation - Google Patents
Novel antigens and methods for their preparationInfo
- Publication number
- HK1003032A1 HK1003032A1 HK98102133A HK98102133A HK1003032A1 HK 1003032 A1 HK1003032 A1 HK 1003032A1 HK 98102133 A HK98102133 A HK 98102133A HK 98102133 A HK98102133 A HK 98102133A HK 1003032 A1 HK1003032 A1 HK 1003032A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- protein
- particle
- hepatitis
- residues
- followed
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 abstract 3
- 239000011246 composite particle Substances 0.000 abstract 3
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 102100031673 Corneodesmosin Human genes 0.000 abstract 2
- 229940096437 Protein S Drugs 0.000 abstract 2
- 108010031318 Vitronectin Proteins 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000320412 Ogataea angusta Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534289A | 1989-07-25 | 1989-07-25 | |
| US38918489A | 1989-08-03 | 1989-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1003032A1 true HK1003032A1 (en) | 1998-09-30 |
Family
ID=27010975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK98102133A HK1003032A1 (en) | 1989-07-25 | 1998-03-13 | Novel antigens and methods for their preparation |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0414374B1 (el) |
| JP (1) | JP3069907B2 (el) |
| KR (1) | KR0181940B1 (el) |
| CN (1) | CN1080304C (el) |
| AT (1) | ATE159031T1 (el) |
| AU (3) | AU5972890A (el) |
| CA (1) | CA2021762C (el) |
| DE (1) | DE69031556T2 (el) |
| DK (1) | DK0414374T3 (el) |
| ES (1) | ES2109921T3 (el) |
| FI (1) | FI903721A0 (el) |
| GR (1) | GR3025819T3 (el) |
| HK (1) | HK1003032A1 (el) |
| HU (1) | HU216013B (el) |
| IE (1) | IE902690A1 (el) |
| IL (1) | IL95153A0 (el) |
| MA (1) | MA21911A1 (el) |
| NO (1) | NO304268B1 (el) |
| NZ (1) | NZ234615A (el) |
| PL (1) | PL168597B1 (el) |
| PT (1) | PT94791B (el) |
| SG (1) | SG48175A1 (el) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86833A0 (en) * | 1987-06-22 | 1988-11-30 | Medico Labs | Peptide containing immunogenic particles |
| PL168408B1 (pl) * | 1989-08-03 | 1996-02-29 | Smithkline Beecham Biolog | Sposób wytwarzania stransformowanego mikroorganizmu PL |
| EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
| IL101651A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Hepatitis b virus surface proteins with reduced host carbohydrate content |
| IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
| US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| MY111880A (en) * | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
| DE69319728T2 (de) | 1992-05-23 | 1999-02-04 | Smithkline Beecham Biolog | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
| SG90042A1 (en) | 1992-06-25 | 2002-07-23 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
| WO1994021292A1 (en) * | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| AT409863B (de) * | 1993-07-30 | 2002-12-27 | Immuno Ag | Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| US5658579A (en) * | 1995-07-31 | 1997-08-19 | The Procter & Gamble Company | Cosmetic powder compositions having improved skin coverage |
| GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| KR100372233B1 (ko) * | 1997-03-12 | 2003-06-11 | 주식회사 코리아나화장품 | 미백 파우더, 그의 제조방법 및 그를 함유하는 메이크업 미백 화장료 |
| EP1797896A1 (en) | 1998-10-16 | 2007-06-20 | GlaxoSmithKline Biologicals SA | Adjuvant systems and vaccines |
| CA2359110A1 (en) * | 1999-01-12 | 2000-07-20 | Ronald James Boon | Combination of hepatitis b vaccine with antiviral agents |
| FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| US7534585B2 (en) | 2003-07-21 | 2009-05-19 | Transgene S.A. | Multifunctional cytokines |
| CA2535562A1 (en) | 2003-08-13 | 2005-03-03 | Chiron Corporation | Improved method of purifying tfpi and tfpi analogs |
| WO2006113528A2 (en) * | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| AU2007293673B2 (en) | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
| DK2468300T3 (da) | 2006-09-26 | 2018-01-29 | Infectious Disease Res Inst | Vaccinesammensætning indeholdende syntetisk adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PL2086582T3 (pl) | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
| AU2007306381B2 (en) | 2006-10-12 | 2011-12-08 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| PE20090212A1 (es) | 2007-05-02 | 2009-03-30 | Glaxosmithkline Biolog Sa | Kit de vacuna para la inmunizacion primaria |
| CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
| CN102038948B (zh) * | 2009-10-10 | 2013-04-10 | 复旦大学 | 一种控制乙型肝炎病毒持续性感染的疫苗 |
| WO2011046218A1 (ja) * | 2009-10-16 | 2011-04-21 | 株式会社カネカ | 抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体 |
| AU2011239706B2 (en) | 2010-04-13 | 2015-08-20 | Celldex Therapeutics Inc. | Antibodies that bind human CD27 and uses thereof |
| GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| CN103596586A (zh) | 2011-04-08 | 2014-02-19 | 免疫设计公司 | 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法 |
| CN103087933B (zh) * | 2011-11-08 | 2015-07-22 | 北京生物制品研究所 | 一种重组多形汉逊酵母菌及其制备方法 |
| HUE044841T2 (hu) | 2012-02-07 | 2019-11-28 | Infectious Disease Res Inst | TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai |
| CN102643349B (zh) * | 2012-04-17 | 2013-12-18 | 中国医学科学院医学生物学研究所 | 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备 |
| ES2787455T3 (es) | 2012-05-16 | 2020-10-16 | Immune Design Corp | Vacunas para el VHS-2 |
| EP2912069B1 (en) | 2012-10-23 | 2019-07-31 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| AU2014373928C1 (en) | 2013-12-31 | 2020-12-17 | Access To Advanced Health Institute | Single vial vaccine formulations |
| WO2016145085A2 (en) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| CN105797151A (zh) * | 2016-03-25 | 2016-07-27 | 汪和睦 | 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗 |
| CA3021328A1 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| US11266602B2 (en) | 2016-05-16 | 2022-03-08 | Infectious Disease Research Institute | PEGylated liposomes and methods of use |
| ES2929054T3 (es) | 2016-05-16 | 2022-11-24 | Access To Advanced Health Inst | Formulación que contiene un agonista de TLR y métodos de uso |
| MX2021010105A (es) | 2016-06-01 | 2022-06-16 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
| WO2018232257A1 (en) | 2017-06-15 | 2018-12-20 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
| MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
| US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| MX2021014363A (es) | 2019-05-25 | 2022-02-21 | Infectious Disease Res Inst | Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante. |
| WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
| IL307519A (en) | 2021-04-09 | 2023-12-01 | Celldex Therapeutics Inc | Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0288198A3 (en) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
-
1990
- 1990-07-19 AT AT90307900T patent/ATE159031T1/de not_active IP Right Cessation
- 1990-07-19 ES ES90307900T patent/ES2109921T3/es not_active Expired - Lifetime
- 1990-07-19 EP EP90307900A patent/EP0414374B1/en not_active Expired - Lifetime
- 1990-07-19 DK DK90307900.2T patent/DK0414374T3/da active
- 1990-07-19 SG SG1996007620A patent/SG48175A1/en unknown
- 1990-07-19 DE DE69031556T patent/DE69031556T2/de not_active Expired - Fee Related
- 1990-07-23 PT PT94791A patent/PT94791B/pt not_active IP Right Cessation
- 1990-07-23 CA CA002021762A patent/CA2021762C/en not_active Expired - Fee Related
- 1990-07-23 MA MA22181A patent/MA21911A1/fr unknown
- 1990-07-23 NZ NZ234615A patent/NZ234615A/xx unknown
- 1990-07-23 IL IL95153A patent/IL95153A0/xx unknown
- 1990-07-23 AU AU59728/90A patent/AU5972890A/en not_active Abandoned
- 1990-07-24 KR KR1019900011386A patent/KR0181940B1/ko not_active IP Right Cessation
- 1990-07-24 IE IE269090A patent/IE902690A1/en unknown
- 1990-07-24 NO NO903285A patent/NO304268B1/no not_active IP Right Cessation
- 1990-07-24 FI FI903721A patent/FI903721A0/fi not_active Application Discontinuation
- 1990-07-25 JP JP2197578A patent/JP3069907B2/ja not_active Expired - Lifetime
- 1990-07-25 PL PL90286209A patent/PL168597B1/pl unknown
- 1990-07-25 CN CN90107172A patent/CN1080304C/zh not_active Expired - Fee Related
- 1990-07-25 HU HU4615/90A patent/HU216013B/hu not_active IP Right Cessation
-
1994
- 1994-10-28 AU AU77528/94A patent/AU7752894A/en not_active Abandoned
-
1997
- 1997-04-18 AU AU18968/97A patent/AU714652B2/en not_active Ceased
- 1997-12-30 GR GR970403469T patent/GR3025819T3/el unknown
-
1998
- 1998-03-13 HK HK98102133A patent/HK1003032A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0414374A3 (en) | Novel antigens and methods for their preparation | |
| KR880009130A (ko) | 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원 | |
| DE3280186D1 (de) | Synthese von menschlichen viralen antigenen mit hilfe von hefe. | |
| EP0401941A3 (en) | Hepatitis b virus surface antigen and production thereof | |
| GR3023985T3 (en) | Expression of hepatitis B S and preS2 proteins in methylotrophic yeasts | |
| NZ206960A (en) | Recombinant antigenic protein containing the amine acid sequence of an epitope of the circumsporozoite protein of a plasmodium species | |
| EP0250253A3 (en) | T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen | |
| HK140095A (en) | Hepatitis surface antigen particle vaccine | |
| MY106731A (en) | Novel antigens and methods therefor | |
| EP0864649A3 (en) | Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation | |
| DE2961060D1 (en) | Antigenic composition useful as a vaccine or vaccine intermediate, and process for preparing same | |
| HK1052368A1 (zh) | 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構 | |
| EP0503252A3 (en) | Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |